Mark A. Hillman - Hillman Value Fund Investment Strategy & Portfolio Analysis
How Hillman Value Fund allocates capital, manages risk, and constructs its portfolio — based on SEC 13F filings.
As of Mar 31, 2026, Mark A. Hillman's Hillman Value Fund portfolio reflects a quant / systematic investor approach across 56 reported 13F positions. Portfolio returns are distributed across holdings, with the top five positions representing approximately 19% of total exposure. Across 56 reported holdings, economic exposure is broadly distributed across healthcare, consumer defensive companies, and technology without dominant single-name concentration. Exposure to high-growth and technology-oriented segments is moderate relative to peers, with performance weighted across healthcare, consumer staples, and basic materials. The portfolio exhibits low turnover, consistent with a buy-and-hold posture held through multiple reporting cycles. Distinctive traits include Long-Term Holder, Broadly Diversified, Economically Diversified.
Investment Style
Value, growth, quality, and behavioral classification from latest 13F holdings.
Primary type: Quant / Systematic Investor
Traits: Long-Term Holder, Broadly Diversified, Economically Diversified, Structurally Diversified
Turnover profile
Moderate
Holding horizon
Long-Term
Portfolio Construction
Concentration and position sizing in the latest filing.
Portfolio construction is lowly concentrated: top three names represent 11.3% of assets, top five 18.7%, and the largest single position is 3.8%.
Top 3 weight
11.3%
Top 5 weight
18.7%
Top 10 weight
35.6%
Largest position
3.8%
Top holdings: Biogen Inc., DuPont de Nemours, Inc., Warner Bros. Discovery, Inc. -, GSK plc, International Flavors & Fragran — view full holdings
Sector Preferences
Where capital is allocated by sector.
Capital is tilted toward Healthcare and Consumer Defensive, with 10 sectors represented in the latest filing.
Leading sectors: Healthcare, Consumer Defensive, Technology
Risk Framework
Concentration, diversification, and turnover tolerance.
This investor accepts low single-name risk (largest position 3.8%, top ten 35.6%) and high economic diversification (HHI 0.01). Turnover tolerance maps to a moderate profile.
Largest position
3.8%
Top 10 weight
35.6%
Max sector
27.9%
Diversification
High
Strategy Evolution
How the strategy changed between the two most recent filing periods.
Dec 31, 2025 → Mar 31, 2026
- Largest holding changed from Warner Bros. Discovery, Inc. - to Biogen Inc..
- Quarter-over-quarter portfolio weight turnover: 13.8%.
For trade-level changes, see the Activity page. View activity.
Similar Investors
Peer group with comparable portfolio behavior.
Similar-investor comparisons are coming soon.